A Phase 2, Randomized, Double Blind, Parallel Design Study Comparing the Efficacy and Safety of VI-0521 to Placebo in the Glycemic Management of Obese Diabetic Adults

Trial Profile

A Phase 2, Randomized, Double Blind, Parallel Design Study Comparing the Efficacy and Safety of VI-0521 to Placebo in the Glycemic Management of Obese Diabetic Adults

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Feb 2015

At a glance

  • Drugs Phentermine/topiramate (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors VIVUS
  • Most Recent Events

    • 24 Feb 2015 Results were presented as per Vivus Inc. media release.
    • 01 Jul 2010 Results of this study were presented at the 70th Annual Scientific Sessions of the American Diabetes Association.
    • 07 Oct 2008 Results presented at the Obesity Society Annual Scientific Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top